Monograph Details
|
|
Central Nervous System
> Seizure disorders
|
|
ZARONTIN |
| Manufacturer |
|
Pfizer Labs |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Succinamide. |
| Generic Name |
|
Ethosuximide 250mg; caps. |
| Also |
|
• ZARONTIN SYRUP
|
| Indications |
|
Absence seizures. |
| Children |
|
Under 3 yrs: not recommended. 3–6 yrs: initially 250mg daily. Over 6 yrs: initially 500mg daily. Increase both every 4–7 days by 250mg daily according to response; max 1.5g daily in divided doses. Usual maintenance: 20mg/kg/day in divided doses. |
| Adults |
|
Initially: 500mg daily. Increase every 4–7 days by 250mg daily according to response; max 1.5g daily in divided doses. |
| Precautions |
|
Impaired hepatic or renal function. Change dose gradually. May precipitate tonic-clonic seizures. Monitor blood, urine and liver tests. Pregnancy (Cat.D). |
| Interactions |
|
Monitor phenytoin, phenobarbital, valproic acid, others. |
| Adverse Reactions |
|
Blood dyscrasias, drowsiness, ataxia, dizziness, hepatic, renal, behavioral, psychological and GI disorders, SLE, Stevens-Johnson syndrome, headache, rash, gingival hyperplasia. |
| How Supplied |
Caps—100
Syrup—pt |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
